Mylan Enjoys Uptick As It Prepares For Pfizer Merger
Executive Summary
With Mylan on track to achieve more than $1bn in new product sales in 2019, recent US launches of the firm’s Wixela Inhub rival to Advair Diskus and Fulphila pegfilgrastim biosimilar helped to propel it to growth in the second quarter, despite still reporting an overall decline in the first half of the year.